CSP Oncology Treatment Guidelines and Targeted Therapies

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/39

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary review of oncology treatment guidelines, oncologic pathophysiological mechanisms, cytotoxic versus targeted agents, and specific oral antineoplastic medications across solid tumors and hematologic malignancies.

40 Terms

1
New cards

Cytotoxic Chemotherapy

Non-selective systemic treatments that target rapidly dividing cells by directly interfering with cell division via antimetabolites, topoisomerase inhibitors, or alkylating agents.

2
New cards

Cytostatic / Targeted Therapies

Therapies that inhibit cancer growth by interfering with specific molecular targets or genetic alterations (such as overexpressed or mutated molecules) involved in tumor progression.

3
New cards

Capecitabine

Xeloda®

oral pyrimidine analog antimetabolite prodrug of fluorouracil (5-FU5\text{-FU})

breast, colorectal, and gastric cancers.

Dosed at 1,000 to 1,250 mg/m21{,}000\text{ to }1{,}250\text{ mg/m}^2 BID for 14 days14\text{ days} on, 7 days7\text{ days} off; contraindicated if CrCl<30 mL/min\text{CrCl} < 30\text{ mL/min}.

4
New cards

Palbociclib

Ibrance®

CDK4/6 inhibitor indicated for HR+/HER2- advanced or metastatic breast cancer.
125 mg125\text{ mg} PO once daily for 21 days21\text{ days} on, 7 days7\text{ days} off of a 28-day cycle

myelosuppression

with food.

5
New cards

Ribociclib

Kisqali®

CDK4/6 inhibitor for HR+/HER2- early or metastatic breast cancer

600 mg600\text{ mg} PO once daily for 21 days21\text{ days} on, 7 days7\text{ days} off

myelosuppression, hepatotoxicity, and QTc prolongation, requiring baseline ECG and LFTs.

6
New cards

Abemaciclib

Verzenio

continuous-dose CDK4/6 inhibitor for breast cancer

BID in combination with AI or 200 mg200\text{ mg} BID as monotherapy;

noted for a high incidence of diarrhea requiring prompt antidiarrheal initiation at the first loose stool.

7
New cards

Neratinib

Nerlynx®

oral HER2+ inhibitor; breast cancer

240 mg240\text{ mg} PO daily with food, associated with a 95%95\% incidence of diarrhea requiring mandatory antidiarrheal prophylaxis unless utilizing a dose-escalation protocol.

8
New cards

Lapatinib

Tykerb®

oral dual tyrosine kinase inhibitor targeting HER2+ breast cancer

taken on an empty stomach

carries a BBW hepatotoxicity.

9
New cards

Tucatinib

Tukysa®

HER2 kinase inhibitor; breast cancer

300 mg300\text{ mg} PO twice daily in combination with trastuzumab and capecitabine

hand-foot syndrome, hepatotoxicity, and stomatitis.

10
New cards

Alpelisib

Piqray®

PI3K inhibitor indicated for PIK3CA-mutated, HR+/HER2- metastatic breast cancer

300 mg300\text{ mg} daily with food

carries substantial risk of hyperglycemia and may require prophylactic metformin.

11
New cards

Olaparib

Lynparza®

PARP inhibitor indicated for BRCA-mutated HER2- breast cancer and recurrent or advanced ovarian/fallopian/peritoneal cancers;

300 mg300\text{ mg} PO twice daily

risk of secondary MDS/AML.

12
New cards

Niraparib

Zejula®

PARP inhibitor used as maintenance in epithelial ovarian, fallopian tube, or primary peritoneal cancer;

baseline dose is individualized to 200 mg200\text{ mg} daily for patients <77 kg< 77\text{ kg} or platelets <150,000/mcL< 150{,}000/\text{mcL}, or 300 mg300\text{ mg} daily if ≥77 kg\ge 77\text{ kg} and ≥150,000/mcL\ge 150{,}000/\text{mcL}.

13
New cards

Osimertinib

Tagrisso®

3rd-generation oral EGFR TKI indicated for EGFR exon 19 deletions, exon 21 L858R mutations, and T790M resistance mutations; lung cancer

requires cardiac monitoring (LVEF assessment) and QTc monitoring.

14
New cards

Erlotinib

Tarceva®

EGFR TKI; lung cancer

taken on an empty stomach

requires avoiding PPIs and careful spacing with H2 blockers, and is subject to reduced plasma concentrations from tobacco smoking.

15
New cards

Afatinib

Gilotrif®

EGFR inhibitor for nonresistant EGFR metastatic mutations; lung cancer

taken on an empty stomach at 40 mg40\text{ mg} daily;

paronychia, rash, stomatitis, and pulmonary interstitial lung disease (ILD).

16
New cards

Alectinib

Alecensa®

2nd-generation ALK inhibitor

600 mg600\text{ mg} PO twice daily with food for ALK+ metastatic NSCLC;

photosensitivity, elevated creatine kinase (CK), edema, and bradycardia/electrolyte abnormalities.

17
New cards

Capmatinib

Tabrecta®

MET tyrosine kinase inhibitor indicated for metastatic NSCLC harboring mutations that lead to MET exon 14 skipping;

400 mg400\text{ mg} PO twice daily.

18
New cards

Sotorasib

Lumakras®

KRAS G12C inhibitor

locally advanced or metastatic KRAS G12C-mutated NSCLC after at least 1 prior systemic therapy;

interacts strongly with acid-reducing agents.

19
New cards

Adagrasib

Krazati®

KRAS G12C inhibitor; NSCLC

edema, QTc prolongation, hepatotoxicity, and gastrointestinal toxicity.

20
New cards

Dabrafenib and Trametinib Combination

Tafinlar + Mekinist

targeted combination of a BRAF inhibitor (Dabrafenib, 150 mg150\text{ mg} BID) and a MEK inhibitor (Trametinib, 2 mg2\text{ mg} daily) indicated for BRAF V600E/K-mutated metastatic melanoma and NSCLC;

prominent adverse effect is pyrexia.

21
New cards

Vismodegib

Erivedge®

Hedgehog signaling pathway inhibitor used for advanced basal cell carcinoma;

carries a BBW for embryo-fetal death or severe birth defects, requiring strict blood donation (24 months24\text{ months}) and semen donation (3 months3\text{ months}) restrictions.

22
New cards

Regorafenib

Stivarga®

multikinase and VEGF inhibitor dosed at 160 mg160\text{ mg} daily on days 1–21 of a 28-day cycle;

requires administration with a low-fat meal (<600 calories< 600\text{ calories}, <30%< 30\% fat)

BBW severe/fatal hepatotoxicity.

23
New cards

Trifluridine / Tipiracil

Lonsurf®

nucleoside metabolic inhibitor combination for refractory metastatic colorectal cancer dosed at 35 mg/m235\text{ mg/m}^2 based on trifluridine BID on days 1–5 and 8–12 of a 28-day cycle;

dose must be held if baseline ANC is <1,500/mm3< 1{,}500/\text{mm}^3 or platelets <75,000/mcL< 75{,}000/\text{mcL}.

24
New cards

Apalutamide

Erleada®

second-generation androgen receptor inhibitor dosed at 240 mg240\text{ mg} daily for castration-sensitive or castration-resistant prostate cancer;

falls, bone fractures, hypertension, and seizures.

25
New cards

Darolutamide

Nubeqa®

androgen receptor antagonist dosed at 600 mg600\text{ mg} PO twice daily with food for nonmetastatic castration-resistant or metastatic hormone-sensitive prostate cancer;

exhibits lower central nervous system penetration, reducing seizure risk.

26
New cards

Abiraterone Acetate

Zytiga®

CYP17 inhibitor dosed at 1,000 mg1{,}000\text{ mg} PO daily on an empty stomach in combination with prednisone (5 mg5\text{ mg} BID) to prevent secondary mineralocorticoid excess (hypertension, hypokalemia, fluid retention).

27
New cards

Gleostine

Lomustine

lipophilic nitrosourea alkylating agent dosed at 130 mg/m2130\text{ mg/m}^2 PO once every 6 weeks for intracranial tumors;

BBW for delayed, dose-related, cumulative, and potentially fatal myelosuppression requiring at least a 6-week count nadir assessment.

28
New cards

Temozolomide

Temodar®

alkylating agent that crosses the blood-brain barrier, indicated for glioblastoma multiforme and anaplastic astrocytoma;

taken on an empty stomach or at bedtime to reduce nausea

billable under Medicare Part B.

29
New cards

Imatinib

Gleevec®

first-generation BCR-ABL tyrosine kinase inhibitor for Ph+ CML; dosed at 400 to 600 mg400\text{ to }600\text{ mg} daily with food and a large glass of water to reduce gastrointestinal irritation

30
New cards

Ponatinib

Iclusig®

potent multi-targeted TKI effective against BCR-ABL with the gatekeeper T315I mutation;

BBW for arterial occlusion events, venous thromboembolism, heart failure, and hepatotoxicity.

31
New cards

Asciminib

Scemblix®

allosteric STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor indicated for Ph+ CML, including patients with the T315I mutation (dosed at 200 mg200\text{ mg} PO twice daily on an empty stomach).

32
New cards

Ibrutinib

Imbruvica®

irreversible Bruton's tyrosine kinase (BTK) inhibitor indicated for CLL (420 mg420\text{ mg} PO daily);

a. fibrillation, bleeding/bruising, and transient lymphocytosis.

33
New cards

Venetoclax

Venclexta®

BCL-2 inhibitor used in CLL and AML; requires a strict 5-week ramp-up dosing schedule (20 mg20\text{ mg}, 50 mg50\text{ mg}, 100 mg100\text{ mg}, 200 mg200\text{ mg}, to 400 mg400\text{ mg} daily) alongside hydration and allopurinol prophylaxis to mitigate high risk of Tumor Lysis Syndrome (TLS).

34
New cards

Gilteritinib

Xospata®

targeted FLT3 inhibitor dosed at 120 mg120\text{ mg} daily for relapsed/refractory AML with a FLT3 mutation;

BBW for differentiation syndrome.

35
New cards

Ivosidenib

Tibsovo®

isocitrate dehydrogenase-1 (IDH1) inhibitor dosed at 500 mg500\text{ mg} daily for IDH1-mutated AML;

BBW differentiation syndrome and causes QTc prolongation.

36
New cards

Immunomodulatory Drugs (IMiDs) REMS Requirements

Mandatory risk evaluation and mitigation strategies for

thalidomide

lenalidomide

pomalidomide

due to severe teratogenicity; limits prescriptions to a maximum 28-day supply with no refills and requires two forms of contraception.

37
New cards

Ixazomib

Ninlaro®

reversible proteasome inhibitor dosed at 4 mg4\text{ mg} on days 1, 8, and 15 of a 28-day cycle with lenalidomide and dexamethasone for multiple myeloma;

must be taken on an empty stomach.

38
New cards

Selinexor

Xpovio®

selective inhibitor of nuclear export (XPO1 inhibitor) indicated for relapsed/refractory multiple myeloma; requires intensive antiemetic prophylaxis (such as a 5-HT3 antagonist) due to severe nausea and anorexia.

39
New cards

Fedratinib

Inrebic®

selective JAK2 and FLT3 inhibitor for primary or secondary myelofibrosis (400 mg400\text{ mg} PO daily);

BBW for encephalopathy, including Wernicke's encephalopathy, requiring mandatory thiamine assessment and supplementation.

40
New cards

Ruxolitinib Phosphate

Jakafi®

JAK1 and JAK2 inhibitor indicated for myelofibrosis and polycythemia vera;

dosed based on baseline platelet count and requires gradual dose tapering upon discontinuation to prevent acute disease flare.